Navigation Links
Vical Announces News Release and Conference Call Schedule for First Quarter 2008 Financial Results

SAN DIEGO, May 1 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced that the company will report financial results for the quarter ended March 31, 2008, before the opening of trading on Thursday, May 8, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Thursday, May 8. The call is open on a listen-only basis to any interested parties. The company will provide details on independent and partnered development programs in the conference call and webcast.

To listen to the conference call, dial in approximately ten minutes before the scheduled call to (888) 600-4883, or (913) 312-6683 for international participants, and reference confirmation code 9467583. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (888) 203-1112, or (719) 457-0820 for international participants, and enter replay passcode 9467583. The call also will be available live and archived through the events page at

Invited analysts and institutional investors may ask questions during the conference call. Others may submit questions before the call by e-mail addressed to or by fax to (858) 646-1150. Submitted questions will be screened for appropriateness and general interest. Selected questions received with sufficient notice before the call will be answered as time permits at the end of the call. For further information, contact Vical's Investor Relations department by phone at (858) 646-1127 or by e-mail at

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Contact: Alan R. Engbring

(858) 646-1127


SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vical Names Andrew de Guttadauro Vice President, Corporate Development
2. Vical to Present at Upcoming Investor Conferences
3. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Vical Announces News Release and Conference Call Schedule for Third Quarter 2007 Financial Results
6. Diamics Receives European CE Mark Approval for Its Pap-Map(TM) System for Cervical Cancer Screening
7. Vical to Present at Investor Conferences
8. Amedica Receives FDA 510(k) Clearance for Valeo(TM) Cervical Plate
9. Vical Presentation at Military Pandemic Influenza Workshop
10. Vical Launches Redesigned Website
11. New Online Learning Tool Fills the Knowledge Gap on Botulinum Toxin Type B for Cervical Dystonia
Post Your Comments:
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the ... the Toronto Stock Exchange, confirms that as of the ... developments that would cause the recent movements in the ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged in ...
(Date:11/24/2015)... LEXINGTON, Massachusetts , November 24, 2015 ... Officer, will participate in the Piper Jaffray 27 th Annual ... on Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. ... Poulton , Chief Financial Officer, will participate in the Piper Jaffray ... City , NY on Tuesday, December 1, 2015, at 8:30 ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... the environment are paramount. Insertion points for in-line sensors can represent a weak ... the InTrac 781/784 series of retractable sensor housings , which are designed ...
(Date:11/24/2015)... 24, 2015 HemoShear Therapeutics, LLC, a ... for metabolic disorders, announced today the appointment of ... of Directors (BOD). Mr. Watkins is the former ... Sciences (HGS), and also served as the chairman ... Powers , Chairman and CEO of HemoShear Therapeutics. ...
Breaking Biology Technology:
(Date:11/19/2015)... -- Although some 350 companies are actively involved in molecular ... according to Kalorama Information. These include Roche Diagnostics, Hologic, Abbott ... of the 6.1 billion-dollar molecular testing market, according to ... Diagnostic s .    ... one company and only a handful of companies can ...
(Date:11/18/2015)... --> --> ... report titled  Gesture Recognition Market - Global Industry Analysis, ... to the report, the global gesture recognition market was valued at ... US$29.1 bn by 2021, at a CAGR of 20.3% ... dominated the global gesture recognition market in ...
(Date:11/17/2015)... 17, 2015 Paris ... --> Paris , qui s,est ... DERMALOG, le leader de l,innovation biométrique, a inventé le ... et empreintes sur la même surface de balayage. Jusqu,ici, ... l,autre pour les empreintes digitales. Désormais, un seul scanner ...
Breaking Biology News(10 mins):